New methods for using stem cells to potentially cure HIV
Novel hematopoietic stem cell engineering and transplantation approaches for HIV cure
['FUNDING_OTHER'] · UNIVERSITY OF SOUTHERN CALIFORNIA · NIH-10831493
This study is exploring a new way to help people with HIV by using specially modified stem cells that can block the virus from entering cells and boost the immune system, with hopes of eventually testing this approach in humans after successful results in mice.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF SOUTHERN CALIFORNIA (nih funded) |
| Locations | 1 site (Los Angeles, UNITED STATES) |
| Trial ID | NIH-10831493 on ClinicalTrials.gov |
What this research studies
This research focuses on engineering hematopoietic stem and progenitor cells (HSPC) to develop advanced gene therapies aimed at curing HIV. By utilizing targeted gene editing techniques, the study seeks to disrupt the CCR5 gene, which is crucial for HIV entry into cells, and enhance the immune response against the virus. The approach includes creating engineered stem cells that can produce antiviral factors and antibodies, potentially providing both local and systemic protection against HIV. The research will be tested in mouse models to evaluate safety and effectiveness before considering human applications.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals living with HIV who are not currently undergoing cancer treatment and are seeking innovative therapeutic options.
Not a fit: Patients who are not infected with HIV or those with advanced cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a functional cure for HIV, significantly improving the quality of life for patients living with the virus.
How similar studies have performed: Previous research has shown promise in gene editing approaches for HIV, particularly in cases similar to the Berlin Patient, indicating potential for success in this novel application.
Where this research is happening
Los Angeles, UNITED STATES
- UNIVERSITY OF SOUTHERN CALIFORNIA — Los Angeles, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: CANNON, PAULA M — UNIVERSITY OF SOUTHERN CALIFORNIA
- Study coordinator: CANNON, PAULA M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.